Newron Pharmaceuticals S.p.A. (SIX: NWRN.SW) Stock Competitors & Peer Comparison
See NWRN.SW's competitors and their performance on the SIX and across the wider stock market.
Peer Comparison Table: Biotechnology Industry
Detailed financial metrics including price, market cap, P/E ratio, and more for NWRN.SW and its SIX peers.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| NWRN.SW | CHF 11.14 | +2.58% | 231.8M | -18.03 | -CHF 0.62 | N/A |
| LONN.SW | CHF 545.60 | +0.11% | 38.1B | 34.25 | CHF 15.93 | +0.92% |
| BANB.SW | CHF 78.55 | +0.77% | 5.9B | 39.51 | CHF 1.99 | +1.15% |
| MOR.SW | CHF 102.00 | +0.00% | 2.4B | -4.03 | -CHF 25.33 | N/A |
| IDIA.SW | CHF 4.84 | -1.22% | 1.3B | -5.59 | -CHF 0.87 | N/A |
| BSLN.SW | CHF 69.00 | +0.00% | 854M | 32.69 | CHF 2.11 | N/A |
| KURN.SW | CHF 16.46 | -4.91% | 649.2M | 90.94 | CHF 0.18 | N/A |
| SANN.SW | CHF 15.94 | +1.27% | 236.4M | -4.16 | -CHF 3.83 | N/A |
| MOLN.SW | CHF 3.46 | +6.46% | 129.8M | -2.55 | -CHF 1.36 | N/A |
| RLF.SW | CHF 2.89 | +0.87% | 36.3M | -2.12 | -CHF 1.36 | N/A |
Stock Comparison
Lonza Group AG (SIX: LONN.SW)
NWRN.SW vs LONN.SW Comparison September 2026
Newron Pharmaceuticals S.p.A. (SIX: NWRN.SW) plays a significant role within the Healthcare sector. Its performance on the SIX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NWRN.SW stands at 231.8M. In comparison, LONN.SW has a market cap of 38.1B. Regarding current trading prices, NWRN.SW is priced at CHF 11.14 on the SIX, while LONN.SW trades at CHF 545.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NWRN.SW currently has a P/E ratio of -18.03, whereas LONN.SW's P/E ratio is 34.25. In terms of profitability, NWRN.SW's ROE is +2.78%, compared to LONN.SW's ROE of -0.01%. Regarding short-term risk, NWRN.SW is more volatile compared to LONN.SW. This indicates higher risk in terms of short-term price fluctuations for NWRN.SW.Check LONN.SW's competition here
Bachem Holding AG (SIX: BANB.SW)
NWRN.SW vs BANB.SW Comparison September 2026
Newron Pharmaceuticals S.p.A. (SIX: NWRN.SW) plays a significant role within the Healthcare sector. Its performance on the SIX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NWRN.SW stands at 231.8M. In comparison, BANB.SW has a market cap of 5.9B. Regarding current trading prices, NWRN.SW is priced at CHF 11.14 on the SIX, while BANB.SW trades at CHF 78.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NWRN.SW currently has a P/E ratio of -18.03, whereas BANB.SW's P/E ratio is 39.51. In terms of profitability, NWRN.SW's ROE is +2.78%, compared to BANB.SW's ROE of +0.10%. Regarding short-term risk, NWRN.SW is more volatile compared to BANB.SW. This indicates higher risk in terms of short-term price fluctuations for NWRN.SW.Check BANB.SW's competition here
MorphoSys AG (SIX: MOR.SW)
NWRN.SW vs MOR.SW Comparison September 2026
Newron Pharmaceuticals S.p.A. (SIX: NWRN.SW) plays a significant role within the Healthcare sector. Its performance on the SIX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NWRN.SW stands at 231.8M. In comparison, MOR.SW has a market cap of 2.4B. Regarding current trading prices, NWRN.SW is priced at CHF 11.14 on the SIX, while MOR.SW trades at CHF 102.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NWRN.SW currently has a P/E ratio of -18.03, whereas MOR.SW's P/E ratio is -4.03. In terms of profitability, NWRN.SW's ROE is +2.78%, compared to MOR.SW's ROE of -1.84%. Regarding short-term risk, NWRN.SW is not fully comparable compared to MOR.SW. This indicates unavailable risk data in terms of short-term price fluctuations for NWRN.SW.Check MOR.SW's competition here
Idorsia Ltd (SIX: IDIA.SW)
NWRN.SW vs IDIA.SW Comparison September 2026
Newron Pharmaceuticals S.p.A. (SIX: NWRN.SW) plays a significant role within the Healthcare sector. Its performance on the SIX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NWRN.SW stands at 231.8M. In comparison, IDIA.SW has a market cap of 1.3B. Regarding current trading prices, NWRN.SW is priced at CHF 11.14 on the SIX, while IDIA.SW trades at CHF 4.84.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NWRN.SW currently has a P/E ratio of -18.03, whereas IDIA.SW's P/E ratio is -5.59. In terms of profitability, NWRN.SW's ROE is +2.78%, compared to IDIA.SW's ROE of +0.27%. Regarding short-term risk, NWRN.SW is less volatile compared to IDIA.SW. This indicates lower risk in terms of short-term price fluctuations for NWRN.SW.Check IDIA.SW's competition here
Basilea Pharmaceutica AG (SIX: BSLN.SW)
NWRN.SW vs BSLN.SW Comparison September 2026
Newron Pharmaceuticals S.p.A. (SIX: NWRN.SW) plays a significant role within the Healthcare sector. Its performance on the SIX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NWRN.SW stands at 231.8M. In comparison, BSLN.SW has a market cap of 854M. Regarding current trading prices, NWRN.SW is priced at CHF 11.14 on the SIX, while BSLN.SW trades at CHF 69.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NWRN.SW currently has a P/E ratio of -18.03, whereas BSLN.SW's P/E ratio is 32.69. In terms of profitability, NWRN.SW's ROE is +2.78%, compared to BSLN.SW's ROE of +0.36%. Regarding short-term risk, NWRN.SW is more volatile compared to BSLN.SW. This indicates higher risk in terms of short-term price fluctuations for NWRN.SW.Check BSLN.SW's competition here
Kuros Biosciences AG (SIX: KURN.SW)
NWRN.SW vs KURN.SW Comparison September 2026
Newron Pharmaceuticals S.p.A. (SIX: NWRN.SW) plays a significant role within the Healthcare sector. Its performance on the SIX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NWRN.SW stands at 231.8M. In comparison, KURN.SW has a market cap of 649.2M. Regarding current trading prices, NWRN.SW is priced at CHF 11.14 on the SIX, while KURN.SW trades at CHF 16.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NWRN.SW currently has a P/E ratio of -18.03, whereas KURN.SW's P/E ratio is 90.94. In terms of profitability, NWRN.SW's ROE is +2.78%, compared to KURN.SW's ROE of +0.10%. Regarding short-term risk, NWRN.SW is less volatile compared to KURN.SW. This indicates lower risk in terms of short-term price fluctuations for NWRN.SW.Check KURN.SW's competition here
Santhera Pharmaceuticals Holding AG (SIX: SANN.SW)
NWRN.SW vs SANN.SW Comparison September 2026
Newron Pharmaceuticals S.p.A. (SIX: NWRN.SW) plays a significant role within the Healthcare sector. Its performance on the SIX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NWRN.SW stands at 231.8M. In comparison, SANN.SW has a market cap of 236.4M. Regarding current trading prices, NWRN.SW is priced at CHF 11.14 on the SIX, while SANN.SW trades at CHF 15.94.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NWRN.SW currently has a P/E ratio of -18.03, whereas SANN.SW's P/E ratio is -4.16. In terms of profitability, NWRN.SW's ROE is +2.78%, compared to SANN.SW's ROE of +6.85%. Regarding short-term risk, NWRN.SW is more volatile compared to SANN.SW. This indicates higher risk in terms of short-term price fluctuations for NWRN.SW.Check SANN.SW's competition here
Molecular Partners AG (SIX: MOLN.SW)
NWRN.SW vs MOLN.SW Comparison September 2026
Newron Pharmaceuticals S.p.A. (SIX: NWRN.SW) plays a significant role within the Healthcare sector. Its performance on the SIX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NWRN.SW stands at 231.8M. In comparison, MOLN.SW has a market cap of 129.8M. Regarding current trading prices, NWRN.SW is priced at CHF 11.14 on the SIX, while MOLN.SW trades at CHF 3.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NWRN.SW currently has a P/E ratio of -18.03, whereas MOLN.SW's P/E ratio is -2.55. In terms of profitability, NWRN.SW's ROE is +2.78%, compared to MOLN.SW's ROE of -0.68%. Regarding short-term risk, NWRN.SW is less volatile compared to MOLN.SW. This indicates lower risk in terms of short-term price fluctuations for NWRN.SW.Check MOLN.SW's competition here
Relief Therapeutics Holding AG (SIX: RLF.SW)
NWRN.SW vs RLF.SW Comparison September 2026
Newron Pharmaceuticals S.p.A. (SIX: NWRN.SW) plays a significant role within the Healthcare sector. Its performance on the SIX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NWRN.SW stands at 231.8M. In comparison, RLF.SW has a market cap of 36.3M. Regarding current trading prices, NWRN.SW is priced at CHF 11.14 on the SIX, while RLF.SW trades at CHF 2.89.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NWRN.SW currently has a P/E ratio of -18.03, whereas RLF.SW's P/E ratio is -2.12. In terms of profitability, NWRN.SW's ROE is +2.78%, compared to RLF.SW's ROE of -0.39%. Regarding short-term risk, NWRN.SW is less volatile compared to RLF.SW. This indicates lower risk in terms of short-term price fluctuations for NWRN.SW.Check RLF.SW's competition here
MindMaze Therapeutics Holding S.A. (SIX: MMTX.SW)
NWRN.SW vs MMTX.SW Comparison September 2026
Newron Pharmaceuticals S.p.A. (SIX: NWRN.SW) plays a significant role within the Healthcare sector. Its performance on the SIX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NWRN.SW stands at 231.8M. In comparison, MMTX.SW has a market cap of 23.4M. Regarding current trading prices, NWRN.SW is priced at CHF 11.14 on the SIX, while MMTX.SW trades at CHF 0.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NWRN.SW currently has a P/E ratio of -18.03, whereas MMTX.SW's P/E ratio is -0.31. In terms of profitability, NWRN.SW's ROE is +2.78%, compared to MMTX.SW's ROE of N/A. Regarding short-term risk, NWRN.SW is less volatile compared to MMTX.SW. This indicates lower risk in terms of short-term price fluctuations for NWRN.SW.Check MMTX.SW's competition here
Spexis AG (SIX: SPEX.SW)
NWRN.SW vs SPEX.SW Comparison September 2026
Newron Pharmaceuticals S.p.A. (SIX: NWRN.SW) plays a significant role within the Healthcare sector. Its performance on the SIX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NWRN.SW stands at 231.8M. In comparison, SPEX.SW has a market cap of 3.9M. Regarding current trading prices, NWRN.SW is priced at CHF 11.14 on the SIX, while SPEX.SW trades at CHF 0.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NWRN.SW currently has a P/E ratio of -18.03, whereas SPEX.SW's P/E ratio is -0.15. In terms of profitability, NWRN.SW's ROE is +2.78%, compared to SPEX.SW's ROE of N/A. Regarding short-term risk, NWRN.SW is less volatile compared to SPEX.SW. This indicates lower risk in terms of short-term price fluctuations for NWRN.SW.Check SPEX.SW's competition here
Addex Therapeutics Ltd (SIX: ADXN.SW)
NWRN.SW vs ADXN.SW Comparison September 2026
Newron Pharmaceuticals S.p.A. (SIX: NWRN.SW) plays a significant role within the Healthcare sector. Its performance on the SIX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NWRN.SW stands at 231.8M. In comparison, ADXN.SW has a market cap of 3.4M. Regarding current trading prices, NWRN.SW is priced at CHF 11.14 on the SIX, while ADXN.SW trades at CHF 0.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NWRN.SW currently has a P/E ratio of -18.03, whereas ADXN.SW's P/E ratio is -0.39. In terms of profitability, NWRN.SW's ROE is +2.78%, compared to ADXN.SW's ROE of -1.31%. Regarding short-term risk, NWRN.SW is less volatile compared to ADXN.SW. This indicates lower risk in terms of short-term price fluctuations for NWRN.SW.Check ADXN.SW's competition here
ObsEva S.A. (SIX: OBSN.SW)
NWRN.SW vs OBSN.SW Comparison September 2026
Newron Pharmaceuticals S.p.A. (SIX: NWRN.SW) plays a significant role within the Healthcare sector. Its performance on the SIX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NWRN.SW stands at 231.8M. In comparison, OBSN.SW has a market cap of 140.6K. Regarding current trading prices, NWRN.SW is priced at CHF 11.14 on the SIX, while OBSN.SW trades at CHF 0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NWRN.SW currently has a P/E ratio of -18.03, whereas OBSN.SW's P/E ratio is -0.00. In terms of profitability, NWRN.SW's ROE is +2.78%, compared to OBSN.SW's ROE of -1.46%. Regarding short-term risk, NWRN.SW is less volatile compared to OBSN.SW. This indicates lower risk in terms of short-term price fluctuations for NWRN.SW.Check OBSN.SW's competition here
Cassiopea S.p.A. (SIX: SKIN.SW)
NWRN.SW vs SKIN.SW Comparison September 2026
Newron Pharmaceuticals S.p.A. (SIX: NWRN.SW) plays a significant role within the Healthcare sector. Its performance on the SIX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NWRN.SW stands at 231.8M. In comparison, SKIN.SW has a market cap of 0. Regarding current trading prices, NWRN.SW is priced at CHF 11.14 on the SIX, while SKIN.SW trades at CHF 35.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NWRN.SW currently has a P/E ratio of -18.03, whereas SKIN.SW's P/E ratio is -28.13. In terms of profitability, NWRN.SW's ROE is +2.78%, compared to SKIN.SW's ROE of -1.27%. Regarding short-term risk, NWRN.SW is less volatile compared to SKIN.SW. This indicates lower risk in terms of short-term price fluctuations for NWRN.SW.Check SKIN.SW's competition here
Polyphor AG (SIX: POLN.SW)
NWRN.SW vs POLN.SW Comparison September 2026
Newron Pharmaceuticals S.p.A. (SIX: NWRN.SW) plays a significant role within the Healthcare sector. Its performance on the SIX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NWRN.SW stands at 231.8M. In comparison, POLN.SW has a market cap of 0. Regarding current trading prices, NWRN.SW is priced at CHF 11.14 on the SIX, while POLN.SW trades at CHF 1.67.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NWRN.SW currently has a P/E ratio of -18.03, whereas POLN.SW's P/E ratio is -0.46. In terms of profitability, NWRN.SW's ROE is +2.78%, compared to POLN.SW's ROE of -1.32%. Regarding short-term risk, NWRN.SW is less volatile compared to POLN.SW. This indicates lower risk in terms of short-term price fluctuations for NWRN.SW.Check POLN.SW's competition here